Alli - Weight Loss Medication: EU Authorization and Usage

Alli, previously known as Orlistat GSK, is an anti-obesity medication authorised for use in the European Union. Its active ingredient, orlistat, aids weight loss in overweight adults with a Body Mass Index (BMI) of 28 kg/m² or higher and should be used in conjunction with a mildly hypocaloric, lower-fat diet. Alli's approval by the European Medicines Agency (EMA) was based on the positive benefit-risk balance determined by the Committee for Medicinal Products for Human Use (CHMP). The medication works by inhibiting fat absorption, aiding weight management. For comprehensive information, including product details, authorisation, and research data, refer to the European Public Assessment Report (EPAR) by the EMA.

If you're looking for a next-gen fat burner with whole-body benefits—not just a temporary thermogenic boost—Mitolyn may be the smarter, longer-lasting choice.